RxDoctor Payments Data

Caroline McCoach

Internal Medicine · San Francisco, CANPI 1225265333

Payments from drug & device makers

$1,285,515in general payments, 2019–2025

Across 47 payments — averaging $27,351 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.2M
  • Pfizer$72K
  • Amgen$20K
  • Takeda Pharmaceuticals U.S.A., Inc.$13K
  • Novartis$9K
  • Genentech, Inc.$2K
  • plus $1K from 2 others
$206in research payments, 2019–2025

Across 1 payment — averaging $206.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$206

What the payments were for

  • Consulting fees$20,10590%
  • Travel & lodging$1,5087%
  • Food & beverage$7833%
  • Education$110%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly16$1,167,609
Pfizer3$71,765
Amgen6$20,231
Takeda Pharmaceuticals U.S.A., Inc.9$13,134
Novartis7$8,908
Genentech, Inc.3$2,447
AstraZeneca2$1,396
E.r. Squibb & Sons, L.L.C.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,285,515 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →